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Abstract
OBJECTIVES: The objective of this retrospective multi-institutional study was to evaluate the postoperative outcomes of video-assisted
thoracoscopic surgery (VATS)-lobectomy (VATS-L) for non-small-cell lung cancer (NSCLC) in patients with impaired lung function. The
second end point was to illustrate the effective role of forced expiratory volume in 1 s (FEV1%) and the diffusing capacity of the lung for
carbon monoxide (DLCO%) in predicting complications in this population.
METHODS: Data from patients who underwent VATS-L at participating centres were analysed and divided into 2 groups: group A com-
prised patients with FEV1% and/or DLCO% >60% and group B included patients with impaired lung function defined as FEV1% and/or
DLCO% <_60%. To define clinical predictors of death and complications, we performed univariate and multivariable regression analyses.
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RESULTS: A total of 5562 patients underwent VATS-L, 809 (14.5%) of whom had impaired lung function. The postoperative mortality
rate did not differ between the 2 groups (2.3% vs 3.2%; P = 0.77). The percentage of patients who had any complication (21.4% vs 34.2%;
P <_ 0.001), the complication rate (28% vs 49.8%; P <_ 0.001) and the length of hospital stay (P <_ 0.001) were higher for patients with limited
pulmonary function. Impaired lung function was a strong predictor of overall and pulmonary complications at multivariable analysis.
CONCLUSIONS: VATS-L for NSCLC can be performed in patients with impaired lung function without increased risk of postoperative
death and with an acceptable incidence of overall and respiratory complications. Our analysis suggested that FEV1% and DLCO% play a
substantial role in estimating the risk of complications after VATS-L, but their role was less reliable for estimating the mortality.
Keywords: Video-assisted thoracoscopic surgery-lobectomy • Non-small-cell lung cancer • Impaired lung function • Forced expiratory
volume in 1 s • Diffusing capacity of the lung for carbon monoxide • Complications
ABBREVIATIONS
CCI Charlson Comorbidity Index
DLCO% Diffusing capacity of the lung for carbon monoxide
ECOG PS Eastern Cooperative Oncology Group Performance
Status
FEV1% Forced expiratory volume in 1s
NSCLC Non-small-cell lung cancer
ppo Predicted postoperative
VATS Video-assisted thoracoscopic surgery
VATS-L Video-assisted thoracoscopic surgery lobectomy
INTRODUCTION
The risk evaluation of lung resection is based on the results of
pulmonary function tests. The forced expiratory volume in 1 s
(FEV1) and the diffusing capacity of the lung for carbon monox-
ide (DLCO) are the parameters that correlate most accurately
with postoperative morbidity and mortality [1, 2]. Current preop-
erative guidelines for the risk assessment [1–3] were established
according to the evidence obtained from large studies on
patients undergoing lung resection through open thoracotomy.
However, nowadays pulmonary lobectomy is frequently per-
formed through a minimally invasive video-assisted thoraco-
scopic surgery (VATS) approach [4–6], and some researchers have
demonstrated that VATS-lobectomy (VATS-L) is associated with
better outcomes than lobectomy via thoracotomy [4–11], even in
patients with suboptimal lung function [12–19]. To clarify the ef-
fective role of VATS-L in this fragile population, we performed a
multi-institutional study to evaluate the postoperative outcomes
of VATS-L for non-small-cell lung cancer (NSCLC) in patients
with impaired pulmonary function and to identify the role of
preoperative FEV1% and DLCO% in predicting mortality rates
and overall and respiratory complications.
MATERIALS AND METHODS
Data source
The Italian VATS Group database is a multicentre, web-based
data system for collecting and reporting clinical characteristics,
patterns of care and outcomes data of patients with NSCLC
treated with a VATS-L. The Italian VATS Group has maintained
this prospective database since January 2014. At the time of the
latest report, there were 55 participating centres (general thoracic
surgery units or services, not individual surgeons, which have
joined on a voluntary basis) and 8000 collected cases. An insti-
tutional review board at each centre has provided the approval
for data collection, transmission, storage and analyses. The cur-
rent analysis was reviewed and approved for scientific merit and
feasibility by the VATS Group Scientific Committee and pre-
sented at the annual VATS Group meeting. To maintain a high
level of accuracy and security of the data, a specific committee
implements rigorous quality assurance and safety procedures for
the VATS Group database [20]. Furthermore, the Italian VATS
Group database received awards from the European Society of
Thoracic Surgeons in September 2017 for data quality and audit-
ing [21]. To be included in the database, patients must meet the
criterion of a VATS-L using a standard approach as defined by
VATS Group policy.
Patient population and methods
The study population comprised patients who received VATS-L
with curative intent as the primary procedure for treating NSCLC
at VATS Group participating centres and who were included in
the VATS Group database between 1 January 2014 and 31
December 2018. We analysed the short-term outcomes of
patients with impaired preoperative lung function who under-
went VATS-L by comparing results from 2 groups: Group A com-
prised patients with normal preoperative lung function and
Group B included patients with limited preoperative lung func-
tion. Impaired lung function was defined as preoperative FEV1%
<60% or preoperative DLCO% <60% or both. The threshold of
60% was chosen based on previous studies demonstrating that
patients with these FEV1% or DLCO% values have an increased
risk of morbidity and death after lung resection [12, 13, 17, 22,
23]. We excluded patients without complete pulmonary function
evaluation and patients who underwent VATS segmentectomy.
Mortality was defined as death within 30 days or during the
same hospital stay; complications were defined as any event that
altered or changed the postoperative course and associated with
therapeutic procedures. The following respiratory complications
were considered ‘any event’: atelectasis, prolonged air leak for
7 days, pulmonary embolism, adult respiratory distress syndrome,
pneumonia, need for mechanical ventilation, atelectasis and spu-
tum retention. All clinical variables (technical and oncological
variables, definitions of complications) were defined by the sci-
entific committee and accepted by each participating centre [20].
Univariate and multivariable analyses were performed regard-
ing postoperative mortality and morbidity rates for selected clini-
cal variables [age, impaired lung function, Eastern Cooperative
Oncology Group Performance Status (ECOG PS), Charlson
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Comorbidity Index (CCI), NSCLC clinical stage] in order to iden-
tify preoperative risk factors.
Statistical analyses
Statistical analyses were performed using SPSS 24.0 (IBM SPSS
Statistics for Macintosh, Version 24.0. Armonk, NY, USA).
Standard descriptive statistics have been used to summarize data
with respect to demographic and oncological characteristics.
Continuous variables, expressed as mean values ± standard devi-
ation and approximately normally distributed, were compared
using the unpaired Student’s t-tests; differences between the me-
dian CCI and ECOG PS were evaluated with the Mann–Whitney
test; categorical variables were analysed using the v2 test or the
Fisher’s exact test as appropriate. A P-value below 0.05 was con-
sidered statistically significant. To define predictors of death,
overall morbidity and pulmonary complications, a univariate ex-
act logistic regression analysis was performed for clinical varia-
bles including patient demographics, comorbidities and
performance status, pulmonary function tests (preoperative
FEV1% and DLCO%) and clinical stage. The logistic model was
checked with the Hosmer–Lemeshow test, which yielded the fol-
lowing P-values: 0.55, 0.42 and 0.61, respectively. Variables asso-
ciated with a P-value <0.20 were selected for the multivariable
logistic regression analysis.
RESULTS
During the same period, 43 921 lung resections for NSCLC (www.
ape.agenas.it) were performed in the selected centres; of these,
5562 patients were included in the Italian VATS Group database
and underwent planned VATS-L with complete pulmonary func-
tion assessment. A total of 809 (14.5%) were defined as patients
with impaired lung function (Fig. 1). Of these, 224 patients had
preoperative FEV1% <60%; 645 had DLCO% <60%; and 60 had
both values lower than 60% of the predicted value.
Patient demographics, clinical and pathological stages, preop-
erative functional status and comorbidities of the 2 groups are
summarized in Table 1.
In group B, we noted a higher proportion of men (P < 0.001), a
higher incidence of chronic obstructive pulmonary disease and
connective disease (both P < 0.001) and significant differences in
the median ECOG PS and CCI (both P < 0.001). The preoperative
absolute values of FEV1 and forced vital capacity in litres and the
preoperative FEV1%, forced vital capacity % and DLCO% were
different between the 2 groups (P < 0.001 respectively). Patients
with poor preoperative pulmonary function more frequently
underwent upper lobectomy (P = 0.025) and had a more ad-
vanced clinical stage (P < 0.001).
Postoperative results
The postoperative outcomes of the 2 groups are depicted in
Table 2. The postoperative mortality rates were 2.3% and 3.2%
(P = 0.77), respectively. Representing the lung function on a 10%-
based scale for FEV1% and DLCO% (Table 3), we observed a pro-
gressive reduction in the mortality rate and in the overall and re-
spiratory complications rate as lung function improved.
Patients who had at least 1 postoperative complication (21.4%
vs 34.2%; P <_ 0.001), the overall complication rate (28% vs 49.8%,
P <_ 0.001), the incidence of pulmonary complications (13.3% vs
23.4%, P <_ 0.001) and the length of hospital stay (6.5 ± 5.5 vs 7.9
± 6.6, P <_ 0.001) were higher in group B. In particular, we ob-
served a significantly higher incidence of atrial arrhythmias
(P < 0.001), prolonged air leak (P < 0.001), pneumonia (P < 0.001),
atelectasis (P < 0.001), sputum retention (P < 0.001), need for me-
chanical ventilation (P < 0.001), bleeding (P = 0.02) and need for
blood transfusions (P < 0.001) in patients with poor lung function.
Patients with both FEV1% and DLCO% <60% were more prone to
Figure 1: Univariate regression line showing the probability of overall complications as a function of preoperative FEV1% (A) and DLCO% (B) for patients undergoing
video-assisted thoracoscopic surgery-lobectomy. The middle line represents the regression line, whereas the 2 lines above and below represent the 95% confidence
limits. The circles show the actual observed occurrence (at the top) and lack of occurrence (at the bottom) associated with the pulmonary function value for each pa-
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Table 1: Demographic and preoperative data, clinical and pathological stages, surgical approaches and perioperative outcomes
Variables Non-impaired lung




Male gender, n (%) 2850 (60) 547 (67.6) <0.001
Age (years), mean ± SD 67.8 ± 9.5 68.1 ± 8.8 0.31
FEV1 (l), mean ± SD 2.4 ± 0.6 2.0 ± 0.6 <0.001
FEV1%, mean ± SD 97.4 ± 18.5 79.4 ± 21.7 <0.001
FVC (l), mean ± SD 103.5 ± 25.1 93.7 ± 31.9 <0.001
FVC%, mean ± SD 103.5 ± 25.1 93.7 ± 31.9 <0.001
FEV1/FVC, mean ± SD 76.2 ± 11.8 68.5 ± 15.8 <0.001
DLCO%, mean ± SD 87.6 ± 16.4 58.7 ± 17.1 <0.001
ECOG PS, median (range) 0 (0–4) 0 (0–4) <0.001
CCI, median (range) 4 (0–15) 5 (0–13) <0.001
Comorbidities, n (%)
CAD 490 (10.3) 110 (13.6) 0.07
COPD 882 (18.6) 357 (44.1) <0.001
Connective disease 121 (2.5) 28 (4.7) <0.001
Peripheral artery disease 763 (16.1) 158 (19.5) 0.016
Diabetes mellitus 640 (13.5) 102 (12.6) 0.53
Other solid tumour 987 (20.8) 169 (20.9) 0.92
Induction treatment 130 (2.7) 46 (5.7) <0.001
Side, n (%) 0.81
Left 1840 (38.7) 317 (39.2)
Right 2913 (61.3) 492 (60.8)
Lower bilobectomy, n (%) 45 (0.9) 5 (0.6) 0.025
Lower lobectomy, n (%) 1673 (35.2) 262 (32.4)
Middle lobectomy, n (%) 384 (8.1) 47 (5.8)
Upper bilobectomy, n (%) 44 (0.9) 6 (0.7)
Upper lobectomy, n (%) 2607 (54.8) 489 (60.4)
Surgical approach, n (%) 0.027
Copenhagen 3474 (73.1) 585 (72.3)
D’Amico 615 (12.9) 111 (13.7)
Uniportal 471 (9.9) 74 (9.1)
Other 193 (4) 39 (4.8)
Systematic lymph node dissection, n (%) 3113 (65.5) 532 (65.8) 0.62
Sampling, n (%) 1617 (34) 271 (33.5)
No dissection, n (%) 23 (0.4) 6 (0.7)
Pathological diagnosis, n (%) <0.001
ADC 3444 (72.5) 553 (68.4)
SCC 729 (15.3) 177 (21.9)
NET 468 (9.8) 62 (7.6)
Other 112 (2.3) 17 (2.1)
Clinical stage, n (%) <0.001
IA 3101 (65.2) 480 (59.3)
IB 799 (16.8) 139 (17.2)
IIA 177 (3.7) 46 (5.7)
IIB 323 (6.8) 52 (6.4)
IIIA 255 (5.4) 66 (8.2)
IIIB 43 (0.9) 12 (1.5)
IIIC 2 (0.1) 0
IV 53 (1.1) 14 (1.7)
Pathological stage, n (%) 0.01
IA 2462 (51.8) 378 (46.7)
IB 1064 (22.4) 205 (25.3)
IIA 208 (4.4) 39 (4.8)
IIB 545 (11.5) 86 (10.6)
IIIA 390 (8.2) 73 (9)
IIIB 47 (1) 18 (2.2)
IIIC 1 (0.1) 0
IV 36 (0.8) 10 (1.2)
Operative time (min), mean ± SD 184.4 ± 71.1 180.8 ± 61.8 0.17
Estimated blood loss (ml), mean ± SD 140.8 ± 165.6 146.9 ± 193.1 0.36
Number of N1 lymph nodes resected, mean ± SD 6.2 ± 4.4 6.43 ± 4.4 0.16
Number of N2 lymph nodes resected, mean ± SD 7 ± 5.1 7.6 ± 5.7 <0.001
ADC: adenocarcinoma; CAD: coronary artery disease; CCI: Charlson Comorbidity Index; COPD: chronic obstructive pulmonary disease; DLCO%: diffusing capacity
of the lung for carbon monoxide; ECOG PS: Eastern Cooperative Oncological Group Performance Status; FEV1: forced expiratory volume in 1 s; FVC: forced vital
capacity; NET: neuroendocrine tumour; SCC: squamous cell carcinoma; SD: standard deviation.
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develop overall and respiratory complications (P < 0.01,
respectively).
Logistic regression: univariate and multivariable
analyses
Univariate predictors of mortality, morbidity and pulmonary
complications with P-value >0.20 were entered into a multivari-
able model. No preoperative factors were significantly associ-
ated with mortality. We observed a trend of significance for
patients with PS >1 (P = 0.07) (Table 4). Excluding the preopera-
tive clinical stage, all variables entered into the model demon-
strated a significant association with overall complications
(Table 5). When we looked at postoperative respiratory compli-
cations (Table 6), the multivariable analysis showed a significant
association between impaired lung function (P < 0.001), CCI <4
(P < 0.001), male sex (P < 0.001), FEV1 <60% (P < 0.001), DLCO
<60% (P < 0.001) and both values <60% (P < 0.001). Figures 1
and 2 represent in a visual manner the association between
preoperative FEV1% or DLCO% and the incidence of overall
and respiratory complications.
Table 2: Postoperative results
Complications Non-impaired lung




AF, n (%) 343 (7.2) 85 (10.5) <0.001
Myocardial infarction, n (%) 8 (0.2) 4 (0.5) 0.08
Cerebrovascular disease, n (%) 14 (0.3) 2 (0.2) 1
Peripheral vascular disease, n (%) 4 (0.1) 1 (0.1) 0.54
Cardiac arrest, n (%) 2 (0.0) 1 (0.1) 1
PAL, n (%) 355 (7.5) 111 (13.7) <0.001
Pulmonary embolism, n (%) 5 (0.1) 1 (0.1) 1
ARDS, n (%) 19 (0.4) 3 (0.4) 1
Pneumonia, n (%) 142 (3) 44 (5.4) <0.001
Mechanical ventilation, n (%) 11 (0.2) 10 (1.2) <0.001
Atelectasis, n (%) 81 (1.7) 29 (3.6) <0.001
Sputum retention, n (%) 129 (2.7) 42 (5.2) <0.001
Haemothorax, n (%) 59 (1.2) 19 (2.3) 0.02
Bronchopleural fistula, n (%) 7 (0.1) 2 (0.2) 0.62
Chylothorax, n (%) 15 (0.3) 1 (0.1) 0.49
Phrenic nerve injury, n (%) 8 (0.2) 2 (0.2) 0.64
Laryngeal nerve injury, n (%) 25 (0.5) 7 (0.9) 0.21
Blood transfusions, n (%) 94 (2) 31 (3.8) <0.001
Renal failure, n (%) 27 (0.6) 8 (1) 0.15
Deaths, n (%) 109 (2.3) 26 (3.2) 0.77
Complication rate, n (%) 1348 (28) 403 (49.8) <0.001
At least 1 complication, n (%) 1016 (21.4) 277 (34.2)
FEV1 <60%, n (%) 1207 (22.6) 86 (38.4) <0.001
DLCO <60%, n (%) 1069 (21.7) 224 (34.7) <0.001
Both, n (%) 1260 (22.9) 33 (55) <0.001
Pulmonary complication, n (%) 634 (13.3) 189 (23.4) <0.001
FEV1 <60%, n (%) 34 (20.7)
DLCO <60%, n (%) 131 (22.4)
Both, n (%) 24 (40)
Length of hospital stay (days), mean ± SD 6.5 ± 5.5 7.9 ± 6.6 <0.001
Conversion rate, n (%) 412 (8.7) 74 (9.1) 0.63
AF: atrial fibrillation; ARDS: adult respiratory distress syndrome; DLCO: diffusing capacity of the lung for carbon monoxide; FEV1: forced expiratory volume in 1 s;
PAL: prolonged air leak; SD: standard deviation.
Table 3: Deaths, overall and respiratory complications and length of hospital stay using a 10%-based scale
Variables FEV1% <40 FEV1% 40–50 FEV1% 50–60 FEV1% 60–70 FEV1% 70–80 FEV1% >80
Deaths, n (%) 0 0 4/171 (2.3) 8/424 (1.8) 13/717 (1.8) 110/4197 (2.6)
At least 1 complication, n (%) 5/10 (50) 20/43 (46.5) 61/171 (35.6) 136/424 (32) 214/717 (29.8) 857/4197 (20.4)
Pulmonary complication, n (%) 3/10 (30) 12/43 (27.9) 43/171 (25.1) 102/424 (24) 158/717 (22) 505/4197 (12)
Length of hospital stay (days), mean ± SD 7.2 ± 3.3 10.9 ± 10 8.1 ± 7.7 7.5 ± 5.9 7.5 ± 7.1 6.4 ± 5.2
Variables, n (%) DLCO% <40% DLCO% 40–50 DLCO% 50–60 DLCO% 60–70 DLCO% 70–80 DLCO% >80
Deaths, n (%) 1/54 (1.8) 11/171 (6.4) 12/420 (2.8) 16/765 (2) 25/1092 (2.2) 70/3060 (2.2)
At least 1 complication, n (%) 14/54 (25.9) 70/171 (40.9) 140/420 (33.3) 197/765 (25.7) 238/1092 (21.7) 634/3060 (20.7)
Pulmonary complications, n (%) 11/54 (20.3) 44/171 (25.7) 100/420 (23.8) 142/765 (18.5) 159/1092 (14.5) 367/3060 (11.9)
Length of hospital stay (days), mean ± SD 6.9 ± 5.2 9 ± 7.7 7.9 ± 6.7 7.3 ± 6.7 6.7 ± 5.6 6.3 ± 5.1
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DISCUSSION
In the last decades, the advantages of VATS-L over a traditional
lobectomy via thoracotomy were assessed in large multi-
institutional retrospective analyses and randomized controlled
trials [4–11, 19, 24]. However, in these studies, patients with poor
lung function were under-represented or not included, so the
outcomes in this fragile population could not be extrapolated.
Consequently, the objective of our study was to report the post-
operative outcomes of VATS-L for NSCLC in patients with im-
paired lung function, defined as preoperative FEV1% and/or
DLCO% <60%, using a web-based Italian VATS-L database (www.
vatsgroup.org).
The major findings of our retrospective multi-institutional
study were as follows: (i) VATS-L is feasible in patients with mar-
ginal lung function without an increased number of deaths; (ii)
postoperative complications were more frequent in this popula-
tion and were strongly associated with preoperative lung func-
tion; and (iii) predicted FEV1% and predicted DLCO% values
maintained their role in predicting the incidence of adverse
events but not of deaths.
In our study, the mortality rate after VATS-L for patients with
poor lung function was 3.2%, a value similar to that of the control
group of patients with normal lung function (P = 0.77) and in line
with the mortality rates (0–14.3%) reported in a previously pub-
lished meta-analysis [14]. Furthermore, we observed an increased
mortality rate (6.2%) in patients who had preoperative DLCO%
values of 40–50%. However, no other paper showed a statistically
significant increase in deaths for patients with impaired lung
function because the overall number of postoperative deaths af-
ter VATS-L was low and the proportion of patients with poor
lung function was too small to identify their statistical impact on
the mortality rate, as was also shown in a multi-institutional
analysis [13]. The debate about the safety of VATS-L in high-risk
patients is on-going. Several historical, single-centre studies dem-
onstrated that, in carefully selected patients, outcomes for
patients who had VATS-L were acceptable and not different in
comparison with the outcomes of patients with standard postop-
erative risk [15, 18, 25]. Our study showed that VATS-L in this
fragile cohort of patients is safe and feasible and that the multi-
institutional nature of this study decreased the influence of indi-
vidual algorithms for patient selection. Therefore, our outcomes
can be generally accepted.
Despite the poor lung function and the presence of comorbid
conditions in our cohort of patients, overall morbidity was 49.8%,
although a large portion of patients had an uneventful postoper-
ative course (65.8%). Furthermore, as shown in Table 2, the ma-
jority of complications were not life-threatening. The incidence
of pulmonary complications was significant, about twice that of
the control group (23.4% vs 13.3%; P < 0.001). We reported a high
incidence of prolonged air leak (13.7%), pneumonia (5.4%), spu-
tum retention (5.2%) and atelectasis (3.6%). As reported by other
Table 4: Univariate and multivariable analysis on mortality
Variables Univariate analysis Multivariable analysis
OR CI 95% P-value OR CI 95% P-value
Male gender 1.15 0.81–1.62 0.42
Impaired lung function 1.41 0.91–2.18 0.12 1.94 0.47–7.97 0.35
Age >70 1.24 0.88–1.75 0.21
ECOG PS >1 2.08 0.95–4.53 0.065 2.05 0.94–4.49 0.070
CCI >4 1.01 0.71–1.42 0.96
cIA 0.99 0.69–1.42 0.98
FEV1 <60% 1.38 0.51–3.77 0.52
DLCO <60% 1.67 1.06–2.62 0.025 3.17 0.74–13.58 0.12
Both >60% 1.39 0.33–5.76 0.64
CCI: Charlson Comorbidity Index; cIA: clinical stage IA; CI 95%: confidence interval at 95%; DLCO: diffusing capacity of the lung for carbon monoxide; ECOG PS:
Eastern Cooperative Oncological Group Performance Status; FEV1: forced expiratory volume in 1 s; OR: odds ratio.
Table 5: Univariate and multivariable analyses on overall complications
Variables Univariate analysis Multivariable analysis
OR CI 95% P-value OR CI 95% P-value
Impaired lung function 1.91 1.63–2.25 <0.001 1.87 1.58–2.2 <0.001
Age >70 1.69 1.49–1.92 <0.001 1.62 1.43–1.84 <0.001
CCI >4 2.08 1.83–2.62 <0.001 1.76 1.53–2.03 <0.001
ECOG PS >1 1.86 1.32–2.62 <0.001 1.56 1.1–2.23 <0.001
Men 1.61 1.4–1.83 <0.001 1.49 1.31–1.71 <0.001
cIA 0.99 0.87–1.12 0.87
FEV1 <60% 2.13 1.61–2.81 <0.001 2.35 1.36–4.06 <0.001
DLCO <60% 1.91 1.61–2.28 <0.001 2.68 1.36–4.06 <0.001
Both <60% 4.11 2.46–6.87 <0.001 2.56 1.39–4.68 <0.001
CCI: Charlson Comorbidity Index; cIA: clinical stage IA; CI 95%: confidence interval at 95%; DLCO: diffusing capacity of the lung for carbon monoxide; ECOG PS:
Eastern Cooperative Oncological Group Performance Status; FEV1: forced expiratory volume in 1 s; OR: odds ratio.






/icvts/advance-article-abstract/doi/10.1093/icvts/ivaa044/5816445 by guest on 09 April 2020
authors [10, 17, 26], we also noted that the incidence of pulmo-
nary complications was inversely proportional to the decrease of
pulmonary function, as represented in Fig. 2. Also, if both preop-
erative FEV1% and DLCO% were low, the pulmonary morbidity
could increase. These adverse events also caused a significantly
prolonged length of hospital stay, and we can assume that it in-
volved an increase in hospital-related costs. The multivariable
analysis on overall morbidity demonstrated that the develop-
ment of complications was multifactorial (Table 5), whereas
pulmonary complications were strongly associated with preoper-
ative lung function, as shown by the significant, high level of the
hazard ratio for both FEV1% and DLCO% (Table 6).
A large number of authors postulated that the advantages of a
VATS-L over a lobectomy through a conventional thoracotomy
were secondary to maintained chest wall mechanics, lower post-
operative pain and preserved postoperative lung function. All
these factors had a positive influence on patients with poor lung
function as reported by several authors [12, 13, 25]. Ceppa et al.
[13], in a multi-institutional study based on data from the
General Thoracic Database of the Society of Thoracic Surgeons
demonstrated that a thoracotomy per se had a strong influence
on predicting pulmonary complications in comparison with
VATS (21.7% vs 17.8%; P < 0.001). Moreover, they showed fewer
complications in patients at high risk (with preoperative FEV1%
<60%) treated with VATS in comparison to a similar group of
subjects who underwent thoracotomy. The effective role of VATS
resection in patients with limited lung function was also con-
firmed by Burt et al. [12]. They reaffirmed the strong predictive
value of preoperative FEV1%, DLCO%, predicted postoperative
(ppo)FEV1% and ppoDLCO% regarding postoperative overall and
cardiopulmonary complications, findings comparable to our
results. On the other hand, Berry et al. [17] showed that the value
Table 6: Univariate and multivariable analyses on pulmonary complications
Variables Univariate analysis Multivariable analysis
OR CI 95% P-value OR CI 95% P-value
Impaired lung function 1.82 1.51–2.19 <0.001 1.81 1.51–2.18 <0.001
ECOG PS >1 0.80 0.53–1.22 0.31
Age >70 1.11 0.94–1.31 0.21
cIA 1.03 0.88–1.2 0.7
CCI >4 1.59 1.34–1.89 <0.001 1.68 1.43–1.96 <0.001
FEV1 <60% 2.9 1.53–2.84 <0.001 1.7 1.15–2.5 <0.001
DLCO <60% 2.01 1.65–2.45 <0.001 1.87 1.51–2.31 <0.001
Both <60% 3.92 2.32–6.61 <0.001 2.31 1.33–4.01 <0.001
Male gender 1.53 1.29–1.81 <0.001 1.53 1.29–1.81 <0.001
CCI: Charlson Comorbidity Index; cIA: clinical stage IA; CI 95%: confidence interval at 95%; DLCO: diffusing capacity of the lung for carbon monoxide; ECOG PS:
Eastern Cooperative Oncological Group Performance Status; FEV1: forced expiratory volume in 1 s; OR: odds ratio.
Figure 2: Univariate regression line showing the probability of pulmonary complications as a function of preoperative FEV1% (A) and DLCO% (B) for patients under-
going video-assisted thoracoscopic surgery-lobectomy. The middle line represents the regression line, whereas the 2 lines above and below represent the 95% confi-
dence limits. The circles show the actual observed occurrence (at the top) and lack of occurrence (at the bottom) associated with the pulmonary function value for
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of pulmonary function tests in predicting complications in high-
risk patients (FEV1% and DLCO% <60%) is still reliable for thora-
cotomy whereas the correlation between the preoperative low
value of both FEV1% and DLCO% and adverse postoperative
events is weak for patients who had VATS-L. In conclusion, these
data from the literature and from our study suggested that cura-
tive resection for NSCLC should not be denied to patients based
only on limited pulmonary function; other clinical factors such as
performance status and the presence of comorbid conditions
should be strongly considered.
Limitations
Our study has several limitations. First, it has all of the inherent
biases associated with a retrospective analysis. Second, the ab-
sence of a comparison with a cohort of patients treated through
thoracotomy represents another limit, but our purpose was to
verify the feasibility and to report the outcomes of VATS-L, which
is currently the preferred approach for treating early-stage
NSCLC. Therefore, we demonstrated the benefits of the mini-
mally invasive approach in patients with impaired preoperative
lung function through the comparison with a population with
normal lung function. Furthermore, we strongly believe that
patients with poor lung function should be referred for minimally
invasive resection and that thoracotomy should be avoided in or-
der to decrease the mortality and morbidity risks. Moreover, tho-
racotomy should be reserved for those with a more advanced
stage and after-induction treatment, though these fragile patients
often had a worse performance status and comorbid conditions
that could preclude any multimodal approach. In these kinds of
patients, complete clinical and oncological evaluations are man-
datory [8] to identify the correct tailored therapeutic approach.
For example, a sublobar lung resection with lymph node assess-
ment could be a reasonable approach [27] or offer to the patient
a non-surgical therapy such as stereotactic body radiation ther-
apy or radiofrequency ablation.
The non-use of ppoFEV1% or ppoDLCO% could be interpreted
as another limit, but other papers reported FEV1% and DLCO%
as valuable and reliable parameters predicting mortality and
morbidity rates after VATS-L [15, 19, 21, 22]. Furthermore, the
ppoFEV1% or ppoDLCO% calculated with different formulas is
not free from biases. We also excluded other parameters used in
the preoperative assessment such as the 6-min walking test or
the maximum rate of oxygen consumption because they are
rarely performed. We did not include them in order to maintain
data accuracy and diminish missing data.
CONCLUSION
In conclusion, curative VATS-L for NSCLC can be safely per-
formed in patients with impaired lung function, defined as pre-
operative FEV1% and/or DLCO% lower than 60%, without an
increased risk of postoperative death and an acceptable inci-
dence of overall and respiratory complications. Our analysis sug-
gested that FEV1% and DLCO% still have important roles in
predicting and estimating the risk of operative overall and respi-
ratory complications after VATS-L, but their role was less reliable
for mortality.
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